Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California. Show more

1150 Veterans Boulevard, South San Francisco, CA, 94080, United States

https://www.nkartatx.com

Biotechnology

Healthcare

Start AI Chat

Market Cap

164.1M

52 Wk Range

$1.31 - $2.74

Previous Close

$2.31

Open

$2.30

Volume

1,305,336

Day Range

$2.30 - $2.66

Enterprise Value

-55.6M

Cash

282.3M

Avg Qtr Burn

-18.69M

Insider Ownership

0.54%

Institutional Own.

82.78%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
NKX019 Details Myasthenia gravis	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
NKX019 (CAR NK cell therapy) Details Systemic lupus erythematosus, Autoimmune disease	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
NKX019 (CAR NK cell therapy) Details B-cell malignancies, Non-Hodgkin lymphoma, B-cell lymphoma	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
NKX019 (CAR NK cell therapy) Details Lupus nephritis	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
NKX019 (CAR NK cell therapy) Details Systemic sclerosis, Idiopathic inflammatory myopathy / myositis, ANCA-Associated Vasculitis	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
NKX101 (CAR-T targeting NKG2D) Details Bone marrow disorder, Acute myeloid leukemia, Cancer, Myelodysplastic syndrome	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.